Pain News and Research

Latest Pain News and Research

FDA approves EUSA's orphan drug ERWINAZE for acute lymphoblastic leukemia

EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, oncology supportive care and critical care, today announced that the US Food and Drug Administration (FDA) has approved its orphan drug ERWINAZE (asparaginase Erwinia chrysanthemi) for the treatment of acute lymphoblastic leukemia (ALL) in patients with hypersensitivity to E. coli-derived asparaginase.

19 Nov 2011

Shire, Shionogi enter agreement to co-develop and co-commercialize ADHD medicines in Japan

Shire plc, the global specialty biopharmaceutical company, announces that it has entered into an agreement with Shionogi & Co. Ltd. of Japan to co-develop and co-commercialize certain of Shire's Attention Deficit Hyperactivity Disorder (ADHD) medicines in Japan.

19 Nov 2011

New, incision-free surgery to manage chronic acid reflux

Adam Vasser would wake up at night choking on partially digested food and liquid. Stomach acid burned the delicate tissue of his throat. "I'd sleep really badly," he said. During the day, he sometimes suffered from heartburn.

19 Nov 2011

Understanding causes of TMJ dysfunction critical to a wellness and drugless approach to care

Understanding the relationship between proper function of the upper cervical spine, cranial bones and temporal-mandibular joint dysfunction (or TMJ dysfunction) is critical to a wellness and drugless approach to care.

19 Nov 2011

UofL Pediatric Emergency Department fellow wins Willis Wingert Award

University of Louisville Pediatric Emergency Department fellow Alyssa Turner, M.D., has been awarded the Willis Wingert Award for her platform presentation at the American Academy of Pediatrics annual meeting.

19 Nov 2011

FDA approves EYLEA for treatment of wet Age-related Macular Degeneration

Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved EYLEA (aflibercept) Injection, known in the scientific literature as VEGF Trap-Eye, for the treatment of patients with neovascular (wet) Age-related Macular Degeneration (AMD) at a recommended dose of 2 milligrams every four weeks for the first 12 weeks, followed by 2 mg every eight weeks.

19 Nov 2011

Deep brain stimulation benefits highly treatment resistant patients with major depressive disorder

Results from the first multi-center pilot study of deep brain stimulation (DBS) for major depressive disorder were published online today by the Journal of Neurosurgery. The study, conducted at three research facilities in Canada, was designed to replicate and build upon an earlier study by Dr. Andres Lozano and Dr. Helen Mayberg which was published in the journal Neuron in 2005.

18 Nov 2011

FDA Commissioner revokes approval of Genentech's Avastin for treatment of mBC

Genentech, a member of the Roche Group, announced today that the FDA Commissioner is revoking the approval of Avastin (bevacizumab) for the treatment of mBC in the United States.

18 Nov 2011

Regeneron receives FDA approval for Eylea to treat wet AMD

The U.S. Food and Drug Administration today approved Eylea (aflibercept) to treat patients with wet (neovascular) age-related macular degeneration (AMD), a leading cause of vision loss and blindness in Americans ages 60 and older.

18 Nov 2011

Tonix to initiate TNX-102 PK and BA study for fibromyalgia

Tonix Pharmaceuticals Holding Corp., a specialty pharmaceutical company developing therapies for challenging disorders of the central nervous system, including fibromyalgia syndrome and post-traumatic stress disorder, will initiate a comparative pharmacokinetic and bioavailability study of TNX-102, a novel dosage oral formulation of cyclobenzaprine for the treatment of FM, following the U.S. Food and Drug Administration clearance of the Company's initial Investigational New Drug Application.

18 Nov 2011

Study: Health insurance premiums soar in all 50 states

A new study confirmed a national trend in employer-sponsored coverage -- higher costs for skimpier benefits.

18 Nov 2011

New framework to improve care for patients with delirium

A new national plan of action provides a roadmap for improving the care of patients with delirium, a poorly understood and often unrecognized brain condition that affects approximately seven million hospitalized Americans each year.

18 Nov 2011

State roundup: Calif. cuts make public health outlook bleak

One thing Gov. Mitch Daniels believes with absolute conviction is that consumers need to pay more of the cost of their health care. ... No one can say Daniels isn't practicing what he preaches. Indiana has been using a version of consumer-driven health care for state employees since 2006. Starting next year, 90 percent of Indiana state workers will be covered by a consumer-driven plan with low premiums and high out-of-pocket expenses for actual care.

18 Nov 2011

Research shows how the bite of a small Texas snake causes extreme pain

Examining venom from a variety of poisonous snakes, a group of researchers at the University of California, San Francisco has discovered why the bite of one small black, yellow and red serpent called the Texas coral snake can be so painful.

17 Nov 2011

EC approves Pfizer's Vyndaqel to treat Transthyretin Familial Amyloid Polyneuropathy

Pfizer announced today that the European Commission has approved Vyndaqel (tafamidis) for the treatment of Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP) in adult patients with stage 1 symptomatic polyneuropathy.

17 Nov 2011

Hemoglobin levels, blood pressure and male gender linked to higher risk of silent strokes in SCA children

Factors such as low hemoglobin levels, increased systolic blood pressure, and male gender are linked to a higher risk of silent cerebral infarcts (SCIs), or silent strokes, in children with sickle cell anemia (SCA), according to results from a large, first-of-its-kind study published online today in Blood, the Journal of the American Society of Hematology (ASH).

17 Nov 2011

Eli Lilly provides $4M in additional funding to IDRI for new TB therapies

Eli Lilly and Company today announced that it is providing more than $4 million in additional funding to the Infectious Disease Research Institute. The funding will allow IDRI to continue its early phase drug discovery efforts focused on identifying new and better therapies in the fight against tuberculosis, including multidrug-resistant strains known as MDR-TB.

17 Nov 2011

Incidences of self harm rises among adolescents: study

A recent large population based study shows that at least one in 12 teenagers commit self-harm. The commonest form of self harm is by cutting or burning, as a way of coping with depression, anxiety or other problems.

17 Nov 2011

Vitamin D and its good and bad effects on the heart

Vitamin D in excess may not be beneficial and may even harm the heart says a new study. Scientists have long known that low levels of the nutrient can hurt the heart, but new research shows that higher than normal levels can make it beat too fast and out of rhythm, a condition called atrial fibrillation. The study was presented at the annual meeting of the American Heart Association.

17 Nov 2011

New possibilities for relief from digestive diseases

As a researcher in neurogastroenterology for 40 years, professor Khalil Bitar has spent his professional life studying the causes of perplexing and what frequently become embarrassing problems for humans—issues such as constipation, diarrhea and colon disease.

17 Nov 2011